The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Fosfomic     [4-(4-amino-6,7-dimethoxy- quinazolin-2...

Synonyms: Hytracin, Hytrinex, Flumarc, Vasomet, terazosin, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of C07127


Psychiatry related information on C07127


High impact information on C07127


Chemical compound and disease context of C07127


Biological context of C07127


Anatomical context of C07127


Associations of C07127 with other chemical compounds


Gene context of C07127


Analytical, diagnostic and therapeutic context of C07127


  1. Terazosin, finasteride, or both in benign prostatic hyperplasia. Thien, T., Lenders, J.W. N. Engl. J. Med. (1997) [Pubmed]
  2. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Kyprianou, N., Benning, C.M. Cancer Res. (2000) [Pubmed]
  3. Effect of withdrawal of terazosin therapy in patients with hypertension. Ruoff, G. Am. J. Med. (1986) [Pubmed]
  4. Pharmacokinetics of terazosin. Sonders, R.C. Am. J. Med. (1986) [Pubmed]
  5. Long-term experience with terazosin for treatment of mild to moderate hypertension. Mersey, J.H. Am. J. Med. (1986) [Pubmed]
  6. Endogenous Excitatory Drive Modulating Respiratory Muscle Activity across Sleep-Wake States. Chan, E., Steenland, H.W., Liu, H., Horner, R.L. Am. J. Respir. Crit. Care Med. (2006) [Pubmed]
  7. Prospective randomized comparison of high energy transurethral microwave thermotherapy versus alpha-blocker treatment of patients with benign prostatic hyperplasia. Djavan, B., Roehrborn, C.G., Shariat, S., Ghawidel, K., Marberger, M. J. Urol. (1999) [Pubmed]
  8. Immobility from administration of the alpha1-adrenergic antagonist, terazosin, in the IVth ventricle in rats. Stone, E.A., Lin, Y., Quartermain, D. Neurosci. Lett. (2003) [Pubmed]
  9. The use and rationale of selective alpha blockade in children with non-neurogenic neurogenic bladder dysfunction. Bogaert, G., Beckers, G., Lombaerts, R. International braz j urol : official journal of the Brazilian Society of Urology. (2004) [Pubmed]
  10. Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy. Zuscik, M.J., Sands, S., Ross, S.A., Waugh, D.J., Gaivin, R.J., Morilak, D., Perez, D.M. Nat. Med. (2000) [Pubmed]
  11. Concomitant administration of terazosin and atenolol for the treatment of essential hypertension. Holtzman, J.L., Kaihlanen, P.M., Rider, J.A., Lewin, A.J., Spindler, J.S., Oberlin, J.A. Arch. Intern. Med. (1988) [Pubmed]
  12. Pharmacology of terazosin. Kyncl, J.J. Am. J. Med. (1986) [Pubmed]
  13. Role of selective alpha 1 blockers in the therapy of hypertension. Kaplan, N.M. Am. J. Med. (1986) [Pubmed]
  14. Comparison of the safety and efficacy of once-daily terazosin versus twice-daily prazosin for the treatment of mild to moderate hypertension. Deger, G. Am. J. Med. (1986) [Pubmed]
  15. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2. Keledjian, K., Kyprianou, N. J. Urol. (2003) [Pubmed]
  16. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. Tanaka, Y., Masumori, N., Itoh, N., Sato, Y., Takahashi, A., Ogura, H., Furuya, S., Tsukamoto, T. J. Urol. (2002) [Pubmed]
  17. Comparison of the cardiovascular actions of dopamine and epinine in the dog. Itoh, H., Kohli, J.D., Rajfer, S.I., Goldberg, L.I. J. Pharmacol. Exp. Ther. (1985) [Pubmed]
  18. Efficacy and safety of intravenous terazosin in hypertensive patients. A preliminary report. Cohen, A. Am. J. Med. (1986) [Pubmed]
  19. Overall safety of terazosin as an antihypertensive agent. Sperzel, W.D., Glassman, H.N., Jordan, D.C., Luther, R.R. Am. J. Med. (1986) [Pubmed]
  20. Preweanling administration of terazosin decreases blood pressure of hypertensive rats in adulthood. McCarty, R., Lee, J.H. Hypertension (1996) [Pubmed]
  21. In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia. Barrow, J.C., Nantermet, P.G., Selnick, H.G., Glass, K.L., Rittle, K.E., Gilbert, K.F., Steele, T.G., Homnick, C.F., Freidinger, R.M., Ransom, R.W., Kling, P., Reiss, D., Broten, T.P., Schorn, T.W., Chang, R.S., O'Malley, S.S., Olah, T.V., Ellis, J.D., Barrish, A., Kassahun, K., Leppert, P., Nagarathnam, D., Forray, C. J. Med. Chem. (2000) [Pubmed]
  22. Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation. Papay, R., Zuscik, M.J., Ross, S.A., Yun, J., McCune, D.F., Gonzalez-Cabrera, P., Gaivin, R., Drazba, J., Perez, D.M. J. Neurochem. (2002) [Pubmed]
  23. Comparative trials of terazosin with other antihypertensive agents. Ruoff, G. Am. J. Med. (1986) [Pubmed]
  24. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. Chon, J.K., Borkowski, A., Partin, A.W., Isaacs, J.T., Jacobs, S.C., Kyprianou, N. J. Urol. (1999) [Pubmed]
  25. Terazosin modifies the content of glycosaminoglycans and the activity of matrix metalloproteinase 2 in the rat ventral prostate. Mitropoulos, D., Papakonstantinou, E., Aletras, A.J., Kalinderis, N., Zervas, A., Hatzichristou, D., Karakiulakis, G. Eur. Urol. (2007) [Pubmed]
  26. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. Keledjian, K., Borkowski, A., Kim, G., Isaacs, J.T., Jacobs, S.C., Kyprianou, N. Prostate (2001) [Pubmed]
  27. Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels. Cabell, K.S., Ma, L., Johnson, P. Biochem. Pharmacol. (1997) [Pubmed]
  28. Alpha-1-adrenergic blockade and lipoprotein metabolism in essential hypertension. Ferrier, C., Beretta-Piccoli, C., Weidmann, P., Mordasini, R. Clin. Pharmacol. Ther. (1986) [Pubmed]
  29. Effect of terazosin on serum lipids. Deger, G. Am. J. Med. (1986) [Pubmed]
  30. Clinical trials with terazosin. General methods. Sperzel, W.D., Luther, R.R., Glassman, H.N. Am. J. Med. (1986) [Pubmed]
  31. Terazosin: an effective once-daily monotherapy for the treatment of hypertension. Dauer, A.D. Am. J. Med. (1986) [Pubmed]
  32. Efficacy of terazosin as an antihypertensive agent. Luther, R.R., Glassman, H.N., Jordan, D.C., Sperzel, W.D. Am. J. Med. (1986) [Pubmed]
WikiGenes - Universities